Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
MAP Pharmaceuticals, Inc. (MAPP) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/01/2013 8-K Quarterly results
01/23/2013 8-K Form 8-K - Current report
11/21/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA Resubmission for LEVADEX® --New PDUFA date April 15, 2013--"
11/01/2012 8-K Quarterly results
Docs: "MAP Pharmaceuticals Reports Third Quarter of 2012 Financial Results"
10/16/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug"
08/29/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "FOR IMMEDIATE DISTRIBUTION"
08/01/2012 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Form of underwriting agreement",
"Opinion of Latham & Watkins LLP",
"FOR IMMEDIATE DISTRIBUTION"
07/31/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "FOR IMMEDIATE DISTRIBUTION"
07/24/2012 8-K Form 8-K - Current report
06/25/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "MAP Pharmaceuticals Provides Update Following Meeting with FDA for LEVADEX ® New Drug Application — Company plans to resubmit in late Q3/early Q4 2012"
05/18/2012 8-K Submission of Matters to a Vote of Security Holders
05/04/2012 8-K Quarterly results
Docs: "MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results"
04/12/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "MAP Pharmaceuticals Provides Update on LEVADEX ® Program MOUNTAIN VIEW, Calif., April 12, 2012 /PRNewswire/ — MAP Pharmaceuticals, Inc. today provided an update on LEVADEX ® , the Company's investigational orally inhaled drug for the potential acute treatment of migraine in adults."
03/29/2012 8-K Form 8-K - Current report
03/29/2012 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
03/27/2012 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "MAP Pharmaceuticals Receives Complete Response Letter from FDA for LEVADEX ® NDA —No new clinical studies requested — — MAP Pharmaceuticals to Host Conference Call on Tuesday, March 27, 8:00 a.m. Eastern Time"
01/27/2012 8-K Form 8-K - Current report
01/17/2012 8-K Form 8-K - Current report
12/02/2011 8-K Form 8-K - Current report
11/08/2011 8-K Form 8-K - Current report
10/17/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/04/2011 8-K Quarterly results
Docs: "MAP Pharmaceuticals Reports Second Quarter of 2011 Financial Results"
08/02/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX ®"
05/26/2011 8-K Form 8-K - Current report
05/24/2011 8-K Submission of Matters to a Vote of Security Holders
05/03/2011 8-K Form 8-K - Current report
03/01/2011 8-K Form 8-K - Current report
02/18/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "MAP PHARMACEUTICALS APPOINTS SCOTT R. WARD AS CHAIRMAN OF THE BOARD OF DIRECTORS"
02/01/2011 8-K Form 8-K - Current report
01/31/2011 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "ALLERGAN AND MAP PHARMACEUTICALS ANNOUNCE COLLABORATION ON LEVADEX™ INVESTIGATIONAL THERAPY FOR ACUTE MIGRAINE — Collaboration Intended to Expand Continuum of Care for Migraine Patients and Portfolio Offering to Neurologists and Pain Specialists in United States"
11/08/2010 8-K Form 8-K - Current report
11/05/2010 8-K Quarterly results
Docs: "MAP Pharmaceuticals Reports Third Quarter of 2010 Financial Results"
10/04/2010 8-K Form 8-K - Current report
09/29/2010 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, between the Company and Lazard Capital Markets LLC, as representative of the several underwriters",
"Opinion of Latham & Watkins LLP",
"FOR IMMEDIATE DISTRIBUTION"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy